Publication

Re-evaluating the potential impact and cost-effectiveness of rotavirus vaccination in 73 Gavi countries: a modelling study

Authored by:

Debellut, F., Clark, A., Pecenka, C., Tate, J., Baral, R., Sanderson, C., ... & Atherly, D.

Full Citation:

Debellut, F., Clark, A., Pecenka, C., Tate, J., Baral, R., Sanderson, C., ... & Atherly, D. 2019. Re-evaluating the potential impact and cost-effectiveness of rotavirus vaccination in 73 Gavi countries: a modelling study. The Lancet Global Health. 7(12).

View Publication

Additional key concepts from this publication:

Vaccines are among the most cost-effective health interventions available.

Key Evidence: This study provided an updated model of the cost-effectiveness of rotavirus vaccination in children younger than 5 years across 73 countries previously or currently eligible for Gavi support. The researchers found evidence that rotavirus vaccination is still a cost-effective investment in Gavi countries, projected to save approximately $484 million (around $48 million per year) from the government perspective and $878 million (around $90 million per year) from the societal perspective between 2018 and 2027, by preventing 158.6 million cases of rotavirus gastroenteritis, 80.7 million outpatient visits, 7.9 million hospitalizations, 14.7 million Disability-Adjusted Life Years, and nearly 600,000 deaths.